ABSTRACT
PURPOSE: This study aimed to develop and validate a scoring system to identify long-term survivors after conventional radiotherapy (RT) for metastatic spinal cord compression (MSCC). PATIENTS AND METHODS: Data from 1,125 patients who had received long-course RT for MSCC were included in this study. Of these patients, 344 survived for over 12 months and 781 died within a year following RT. Based on differences between the distributions of patient characteristics in the two groups, a scoring system was developed. Scores ranged from 0 to 18 points and 15 points was selected as the cutoff for identifying long-term survivors. Data from the 1,125 long-course RT patients (test group) were compared to data from 773 patients receiving short-course RT (validation group). RESULTS: A score of ≥ 15 points was associated with a 94 % proportion of long-term survivors. The 15-point cutoff resulted in a specificity of 98 % and a positive predictive value of 94 % for identification of long-term surviving patients. The proportions of long-term survivors for each scoring point in the validation group were very similar to those in the test group. CONCLUSION: This new scoring system enabled identification of long-term survivors after RT for MSCC with very high specificity and positive predictive value. The score proved to be valid and reproducible.
Subject(s)
Spinal Cord Compression/mortality , Spinal Cord Compression/radiotherapy , Spinal Neoplasms/mortality , Spinal Neoplasms/radiotherapy , Spinal Neoplasms/secondary , Survivors , Aged , Disease Progression , Female , Germany , Humans , Long-Term Care , Male , Middle Aged , Neurologic Examination , Particle Accelerators , Radiotherapy Planning, Computer-AssistedABSTRACT
BACKGROUND: This study aimed to identify independent prognostic factors and to create a survival score for patients with metastatic spinal cord compression (MSCC) from colorectal cancer (CRC). PATIENTS AND METHODS: Data from 121 patients irradiated for MSCC from CRC were retrospectively analyzed. Eleven potential prognostic factors were investigated including tumor type, age, gender, Eastern Cooperative Oncology Group performance status score (ECOG-PS), number of involved vertebrae, ambulatory status prior to radiotherapy (RT), other bone metastases, visceral metastases, interval from cancer diagnosis to RT of MSCC, time of developing motor deficits prior to RT, and the RT schedule. RESULTS: On multivariate analysis, improved motor function was significantly associated with an ECOG-PS of 1-2 (p = 0.011) and a slower development of motor deficits (p < 0.001). Improved local control was significantly associated with absence of visceral metastases (p = 0.043) and longer-course RT (p = 0.008). Improved survival was significantly associated with an ECOG-PS of 1-2 (p < 0.001), ambulatory status (p < 0.001), absence of visceral metastases (p < 0.001), and a slower development of motor deficits (p = 0.047). These four prognostic factors were included in a survival score. The score for each factor was determined by dividing the 6-month survival rate by 10. The prognostic score represented the sum of the factor scores. Four prognostic groups were designed; the 6-month survival rates were 0% for 8-12 points, 26% for 13-18 points, 62% for 20-23 points, and 100% for 24-27 points (p < 0.001). CONCLUSION: This study identified several independent prognostic factors for treatment outcomes in patients irradiated for MSCC from CRC. The survival prognosis of these patients can be estimated with a new score.
Subject(s)
Colorectal Neoplasms/radiotherapy , Spinal Cord Compression/mortality , Spinal Cord Compression/radiotherapy , Spinal Neoplasms/radiotherapy , Spinal Neoplasms/secondary , Activities of Daily Living/classification , Aged , Cohort Studies , Colorectal Neoplasms/mortality , Colorectal Neoplasms/pathology , Disease Progression , Female , Humans , Male , Middle Aged , Mobility Limitation , Models, Statistical , Multivariate Analysis , Neoplasm Staging , Neurologic Examination/radiation effects , Prognosis , Retreatment , Retrospective Studies , Spinal Cord Compression/pathology , Spinal Neoplasms/mortality , Spinal Neoplasms/pathology , Survival RateABSTRACT
BACKGROUND: The optimal treatment for patients with a single brain metastasis is controversial. This study investigated the value of a radiation boost given in addition to neurosurgerical resection and whole-brain irradiation (WBI). PATIENTS AND METHODS: In this retrospective study, outcome data of 105 patients with a single brain metastasis receiving metastatic surgery plus WBI (S + WBI) were compared to 90 patients receiving the same treatment plus a boost to the metastatic site (S + WBI + B). The outcomes that were compared included local control of the resected metastasis (LC) and overall survival (OS). In addition to the treatment regimen, eight potential prognostic factors were evaluated including age, gender, performance status, extent of metastatic resection, primary tumor type, extracerebral metastases, recursive partitioning analysis (RPA) class, and interval from first diagnosis of cancer to metastatic surgery. RESULTS: The LC rates at 1 year, 2 years, and 3 years were 38%, 20%, and 9%, respectively, after S + WBI, and 67%, 51%, and 33%, respectively, after S + WBI + B (p = 0.002). The OS rates at 1 year, 2 years, and 3 years were 52%, 25%, and 19%, respectively, after S + WBI, and 60%, 40%, and 26%, respectively, after S + WBI + B (p = 0.11). On multivariate analyses, improved LC was significantly associated with OP + WBI + B (p = 0.006) and total resection of the metastasis (p = 0.014). Improved OS was significantly associated with age ≤ 60 years (p = 0.028), Karnofsky Performance Score > 70 (p = 0.015), breast cancer (p = 0.041), RPA class 1 (p = 0.012), and almost with the absence of extracerebral metastases (p = 0.05). CONCLUSION: A boost in addition to WBI significantly improved LC but not OS following resection of a single brain metastasis.
Subject(s)
Brain Neoplasms/secondary , Brain Neoplasms/therapy , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/therapy , Neurosurgical Procedures/mortality , Radiotherapy, Conformal/mortality , Aged , Aged, 80 and over , Brain Neoplasms/mortality , Combined Modality Therapy/mortality , Female , Germany/epidemiology , Humans , Male , Middle Aged , Prevalence , Risk Assessment , Risk Factors , Survival Analysis , Survival Rate , Treatment OutcomeABSTRACT
BACKGROUND: Zoledronic acid was demonstrated to reduce the rate of skeletal-related events, a hypernym including various outcomes, in patients with bone metastases. In contrast to other studies, this matched-pair analysis focused solely on the impact of zoledronic acid on metastatic spinal cord compression (MSCC). PATIENTS AND METHODS: Data from 98 patients with MSCC receiving radiotherapy plus zoledronic acid were matched 1:2 to 196 patients receiving radiotherapy alone for ten potential prognostic factors. Both groups were compared for local control of MSCC within the irradiated region, overall control of MSCC (local and distant MSCC control), and survival. RESULTS: The 1-year local control rates were 90% after radiotherapy plus zoledronic acid and 81%, after radiotherapy alone (p = 0.042). The 1-year overall control rates were 87% and 75%, respectively (p = 0.016), and the 1-year survival rates were 60% and 52%, respectively (p = 0.17). Results were significant in the Cox proportional hazards model regarding local control (p = 0.024) and overall control (p = 0.008). CONCLUSION: According to the results of this study, zoledronic acid was associated with improved control of MSCC in irradiated patients.
Subject(s)
Diphosphonates/therapeutic use , Imidazoles/therapeutic use , Radiotherapy, Conformal/mortality , Spinal Cord Compression/drug therapy , Spinal Cord Compression/prevention & control , Spinal Neoplasms/secondary , Spinal Neoplasms/therapy , Aged , Bone Density Conservation Agents/administration & dosage , Chemotherapy, Adjuvant/methods , Chemotherapy, Adjuvant/mortality , Comorbidity , Female , Germany/epidemiology , Humans , Male , Middle Aged , Prevalence , Risk Factors , Spinal Cord Compression/mortality , Spinal Neoplasms/mortality , Survival Analysis , Survival Rate , Treatment Outcome , Zoledronic AcidABSTRACT
BACKGROUND: This retrospective study aimed to identify prognostic factors for local control and survival in 214 patients irradiated for spinal cord compression (SCC) from myeloma. PATIENTS AND METHODS: Ten potential prognostic factors were investigated including age, gender, Eastern Cooperative Oncology Group performance score (ECOG-PS), number of involved vertebrae, ambulatory status, other osseous lesions, extraosseous lesions, interval from first diagnosis of myeloma to SCC, time developing motor deficits before radiotherapy (RT), and the RT schedule (short-course vs. long-course RT). RESULTS: On univariate analysis, no factor was associated with local control of SCC. Survival was associated with ECOG-PS (p < 0.001), ambulatory status (p < 0.001), other osseous lesions (p < 0.001), and extraosseous lesions (p < 0.001). On multivariate analysis, these prognostic factors maintained significance. CONCLUSION: New independent prognostic factors were identified for survival after RT of SCC from myeloma. These factors can help tailor treatment to the individual patient.
Subject(s)
Multiple Myeloma/mortality , Multiple Myeloma/radiotherapy , Spinal Cord Compression/mortality , Spinal Cord Compression/radiotherapy , Spinal Cord Neoplasms/mortality , Spinal Cord Neoplasms/radiotherapy , Adult , Aged , Aged, 80 and over , Europe/epidemiology , Female , Humans , Male , Middle Aged , Prevalence , Risk Assessment , Risk Factors , Survival Analysis , Survival Rate , Treatment OutcomeABSTRACT
BACKGROUND: This study was performed to identify new significant prognostic factors in breast cancer patients irradiated for metastatic spinal cord compression (MSCC). PATIENTS AND METHODS: The data of 504 patients with breast cancer patients with MSCC were retrospectively analyzed with respect to posttreatment motor function, local control of MSCC, and survival. The investigated potential prognostic factors included age, Eastern Cooperative Oncology Group (ECOG) performance score, number of involved vertebrae, other bone metastases, visceral metastases, pretreatment ambulatory status, interval from cancer diagnosis to radiotherapy of MSCC, time developing motor deficits before radiotherapy, and the radiation schedule. RESULTS: On multivariate analysis, better functional outcome was associated with ambulatory status prior to RT (estimate - 1.29, p < 0.001), no visceral metastases (estimate - 0.52, p = 0.020), and slower development of motor deficits (estimate + 2.47, p < 0.001). Improved local control was significantly associated with no other bone metastases (risk ratio (RR) 4.33, 95% confidence interval (CI) 1.36-14.02, p = 0.013) and no visceral metastases (RR 3.02, 95% CI 1.42-6.40, p = 0.005). Improved survival was significantly associated with involvement of only 1-2 vertebrae (RR 1.27, 95% CI 1.01-1.60, p = 0.044), ambulatory status before radiotherapy (RR 1.75, 95% CI 1.23-2.50, p = 0.002), no other bone metastases (RR 1.93, 95% CI 1.18-3.13, p = 0.009), no visceral metastases (RR 7.60, 95% CI 5.39-10.84, p < 0.001), and time developing motor deficits before radiotherapy (RR 1.55, 95% CI 1.30-1.86, p < 0.001). CONCLUSION: Several new independent prognostic factors were identified for treatment outcomes. These prognostic factors should be considered in future trials and may be used to develop prognostic scores for breast cancer patients with MSCC.
Subject(s)
Breast Neoplasms/radiotherapy , Lumbar Vertebrae , Spinal Cord Compression/radiotherapy , Spinal Neoplasms/radiotherapy , Spinal Neoplasms/secondary , Thoracic Vertebrae , Activities of Daily Living/classification , Aged , Antiemetics/administration & dosage , Cohort Studies , Dexamethasone/administration & dosage , Female , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Lumbar Vertebrae/radiation effects , Magnetic Resonance Imaging , Middle Aged , Mobility Limitation , Multivariate Analysis , Neoplasm Staging , Neurologic Examination/radiation effects , Prognosis , Proportional Hazards Models , Retrospective Studies , Spinal Cord Compression/mortality , Spinal Cord Compression/pathology , Spinal Neoplasms/mortality , Spinal Neoplasms/pathology , Survival Analysis , Thoracic Vertebrae/radiation effects , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: Patients with metastatic spinal cord compression (MSCC) from non-small cell lung cancer (NSCLC) have an unfavorable prognosis compared to most other MSCC patients. This study was performed to identify prognostic factors for functional outcome and survival in these patients after radiotherapy (RT) alone. PATIENTS AND METHODS: Data of 356 patients irradiated for MSCC from NSCLC were retrospectively analyzed. Ten potential prognostic factors were investigated including age, gender, Eastern cooperative Oncology Group performance score (ECOG-PS), number of involved vertebrae, pre-RT ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to RT of MSCC, time developing motor deficits before RT, and the radiation schedule. RESULTS: On multivariate analysis, better functional outcome was associated with pre-RT ambulatory status (estimate: - 0.84, p = 0.022), no visceral metastases (estimate: - 1.15, p < 0.001), interval from cancer diagnosis to RT of > 15 months (estimate: + 0.48, p = 0.019), and slower (> 7 days) development of motor deficits (estimate: + 1.56, p < 0.001). On multivariate analysis, improved survival was significantly associated with female gender (risk ratio (RR) 1.32, p = 0.043), ECOG-PS 1-2 (RR 1.45, p = 0.034), pre-RT ambulatory status (RR 0.58, p < 0.001), no other bone metastases (RR 1.38, p = 0.010), no visceral metastases (RR 2.87, p < 0.001), interval from cancer diagnosis to RT of > 15 months (RR 0.84, p = 0.035), and slower (> 7 days) development of motor deficits (RR 0.78, p < 0.001). CONCLUSION: This study identified additional independent prognostic factors for outcomes after radiotherapy of MSCC from NSCLC. These prognostic factors can be used for stratification in future trials and can help develop prognostic scores for MSCC from NSCLC.
Subject(s)
Carcinoma, Non-Small-Cell Lung/radiotherapy , Carcinoma, Non-Small-Cell Lung/secondary , Lung Neoplasms/radiotherapy , Spinal Cord Compression/radiotherapy , Spinal Neoplasms/radiotherapy , Spinal Neoplasms/secondary , Age Factors , Aged , Carcinoma, Non-Small-Cell Lung/diagnosis , Carcinoma, Non-Small-Cell Lung/mortality , Disability Evaluation , Female , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/mortality , Magnetic Resonance Imaging , Male , Middle Aged , Multivariate Analysis , Neurologic Examination , Prognosis , Retrospective Studies , Sex Factors , Spinal Cord/pathology , Spinal Cord Compression/diagnosis , Spinal Cord Compression/mortality , Spinal Neoplasms/diagnosis , Spinal Neoplasms/mortality , Survival Rate , Tomography, X-Ray Computed , Tumor BurdenABSTRACT
BACKGROUND: This study aimed to develop and validate a survival scoring system for patients with metastatic spinal cord compression (MSCC) from prostate cancer. PATIENTS AND METHODS: Of 436 patients, 218 patients were assigned to the test group and 218 patients to the validation group. Eight potential prognostic factors (age, performance status, number of involved vertebrae, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, time developing motor deficits) plus the fractionation regimen were retrospectively investigated for associations with survival. Factors significant in the multivariate analysis were included in the survival score. The score for each significant prognostic factor was determined by dividing the 6-month survival rate (%) by 10. The total score represented the sum of the scores for each factor. The prognostic groups of the test group were compared to the validation group. RESULTS: In the multivariate analysis of the test group, performance status, ambulatory status, other bone metastases, visceral metastases, and interval from cancer diagnosis to radiotherapy were significantly associated with survival. Total scores including these factors were 20, 21, 22, 24, 26, 28, 29, 30, 31, 32, 33, 35, 37, or 39 points. In the test group, the 6-month survival rates were 6.5% for 20-24 points, 44.6% for 26-33 points, and 95.8% for 35-39 points (p < 0.0001). In the validation group, the 6-month survival rates were 7.4%, 45.4%, and 94.7%, respectively (p < 0.0001). CONCLUSIONS: Because the survival rates of the validation group were almost identical to the test group, this score can be considered valid and reproducible.
Subject(s)
Proportional Hazards Models , Prostatic Neoplasms/complications , Spinal Cord Compression/etiology , Spinal Cord Compression/mortality , Spinal Neoplasms/complications , Spinal Neoplasms/secondary , Survival Analysis , Adult , Age Distribution , Aged , Aged, 80 and over , Comorbidity , Germany/epidemiology , Humans , Male , Middle Aged , Prevalence , Prostatic Neoplasms/mortality , Prostatic Neoplasms/radiotherapy , Risk Assessment/methods , Risk Factors , Spinal Cord Compression/prevention & control , Spinal Neoplasms/mortality , Spinal Neoplasms/prevention & control , Survival Rate , Treatment OutcomeABSTRACT
PURPOSE: In clinical brachytherapy, there is a tendency to replace continuous low-dose-rate (LDR) irradiation by either single-dose or fractionated high-dose-rate (HDR) irradiation. In this study, the equivalence of LDR treatments and fractionated HDR (2 fractions/day) or pulsed-dose-rate (PDR, 4 fractions/day) schedules in terms of tumor cure was investigated in an experimental tumor model. METHODS AND MATERIALS: Tumors (rat rhabdomyosarcoma R1M) were grown s.c. in the flank of rats and implanted with 4 catheters guided by a template. All interstitial radiation treatment (IRT) schedules were given in the same geometry. HDR was given using an (192)Ir single-stepping source. To investigate small fraction sizes, part of the fractionated HDR and PDR schedules were applied after an external irradiation (ERT) top-up dose. The endpoint was the probability of tumor control at 150 days after treatment. Cell survival was estimated by excision assay. RESULTS: Although there was no fractionation effect for fractionated HDR given in 1 or 2 fractions per day, TCD(50)-values were substantially lower than that for LDR. A PDR schedule with an interfraction interval of 3 h (4 fractions/day), however, was equivalent to LDR. The combination of ERT and IRT resulted in a remarkably increased tumor control probability in all top-up regimens, but no difference was found between 2 or 4 fractions/day. Catheter implantation alone decreased the TCD(50) for single-dose ERT already by 17.4 Gy. Cell viability assessed at 24 h after treatment demonstrated an increased effectiveness of interstitial treatment, but, after 10 Gy ERT followed by 10 Gy IRT (24-h interval), it was not less than that calculated for the combined effect of these treatments given separately. CONCLUSION: In full fractionation schedules employing large fractions and long intervals, the sparing effect of sublethal damage repair may be significantly counteracted by reoxygenation. During 3-h intervals, however, repair may be largely completed with only partial reoxygenation causing PDR schedules to be less effective than fractionated HDR, and equivalent to LDR. Brachytherapy with clinically sized fractions after a large external top-up dose showed a remarkable increase in tumor control rate with no effect of fractionation (up to 4 fractions/day), which could not be fully explained by differences in dose distribution or in the cell viability assessed after treatment. This suggests a longer lasting effect on cell survival or radiosensitivity associated with catheter implantation shortly after the top-up dose.
Subject(s)
Brachytherapy/methods , Dose Fractionation, Radiation , Rhabdomyosarcoma/radiotherapy , Animals , Cell Survival , Dose-Response Relationship, Radiation , Female , Logistic Models , Models, Animal , Neoplasm Transplantation , Radiobiology , Rats , Time FactorsABSTRACT
BACKGROUND AND PURPOSE: First, the aim was to determine the survival and quality of life after reirradiation of relapsing primary malignant brain tumours. The second aim was to assess the influence of a set of potentially prognostic factors on survival. MATERIALS AND METHODS: Forty-two patients received reirradiation for recurring primary brain tumours. The interval between the two consecutive treatments was at least 1 year. External beam irradiation for the initial and recurrent tumour was usually delivered with two opposing lateral fields or two wedged fields in orthogonal directions. The median physical doses of the first and second radiation course were 50 and 46 Gy, respectively. The median cumulative biological equivalent doses (BED) were 200.4 (alpha/beta = 2 Gy) and 115.2 Gy (alpha/beta = 10 Gy). During follow-up, corticosteroid medication and the WHO-performance were registered at regular intervals. The radiological response was assessed by reviewing all available CT- and MRI-films. Potentially prognostic factors with respect to survival were evaluated by both univariate and multivariate analyses. RESULTS: A clinical response (i.e. clinical improvement) was seen in 24% of the patients. Of the evaluable patients, nearly one-third showed a complete (8%) or partial (22%) radiological response. The median overall survival (OS) and progression-free survival (PFS) after retreatment were 10.9 and 8.6 months, respectively. By multivariate analysis, four independent prognostic factors for survival were identified: (1), the WHO-score before retreatment (P = 0.002); (2), the length of the interval between treatments (P = 0.008); (3), the tumour histology; and (4), the response to initial treatment (P values, 0.04). The median survival times for patients with WHO-scores of 0-1 and > or = 2 were 14.0 and 7.4 months, respectively. Patients with oligodendrogliomas had a median OS of 27.5 months, whereas patients with astrocytomas had a median OS of 6.9 months after retreatment. Long-term complications of retreatment were seen in three patients, all of whom had a cumulative BED(2) of > 204 Gy (with alpha/beta = 2 Gy). The quality of life after retreatment, however, was well preserved in the majority of patients. They remained ambulant and capable of self-care until the time of progression which occurred after 8.6 months (median PFS). CONCLUSIONS: After an initial treatment with radiation up to tolerance levels of normal brain tissue, reirradiation of recurring primary brain tumours seems feasible. During the time until clinical progression, patients remained independent with a reasonable quality of life.
Subject(s)
Brain Neoplasms/radiotherapy , Cranial Irradiation , Neoplasm Recurrence, Local/radiotherapy , Adrenal Cortex Hormones/therapeutic use , Adult , Brain Neoplasms/drug therapy , Brain Neoplasms/mortality , Female , Humans , Male , Multivariate Analysis , Neoplasm Recurrence, Local/mortality , Prognosis , Proportional Hazards Models , Quality of Life , Radiotherapy Dosage , Survival Analysis , Treatment OutcomeABSTRACT
Short-term exposure of mice to low O3 doses, as defined by the product of concentration and exposure time (ct), was observed to induce alterations in two enzyme systems: first, that leading to changes in hepatic reduced ascorbic acid (RAA) content, and second to changes in plasma creatine phosphokinase (CPK) activity. RAA alterations were noticed immediately, 30 min and 120 min after termination of the exposure period, whereas CPK showed alterations immediately and 15 min after termination of the exposure. Later determinations, i.e., 24 hr after O3 exposure for RAA and 30 min after 03 exposure for CPK, revealed no significant differences when compared to control animals. Although differences in sensitivity existed, the dose response curves for both systems were more or less similar, showing a short decrease for the initial very low O3 doses, followed by a profound rise and a gradual decrease to control levels for subsequent ct doses. Exceptions were the 30 min curve for RAA and the immediate curve for CPK in so far as that both showed an additional depression. Neither plasma histamine nor plasma lactic acid dehydrogenase (LDH3) were observed to be altered by the range of O3 doses employed. These findings were explained on the basis of adaptation of the organism to a potentially noxious O3 stimulus by enhanced metabolic processes: a weak stimulus leading to only a small adjustment, and stronger stimuli to elevated enzyme activity as well. With increasing doses of O3 this elevation in enzyme activity was found to be gradually diminished, possibly due to a steadily growing demand, leaving the overshoot becoming continually smaller until a balanced state is achieved.
Subject(s)
Enzymes/metabolism , Ozone/toxicity , Air/analysis , Animals , Ascorbic Acid/metabolism , Creatine Kinase/blood , Histamine/blood , L-Lactate Dehydrogenase/blood , Liver/metabolism , Male , Mice , Ozone/analysisABSTRACT
Approximately 15% of our highly inbred C57BL/6 mice show a spleen with a pigmented cranial part. Microscopically, abundant aggregates of pigment granules are observed primarily scattered between cells of the red pulp. They give a positive reaction with Perls' Prussian blue and stain heavily with silver-methenamine. Most of the granules are stored in macrophages. In some cases a number of granules are surrounded by a membrane. This abnormality may be designated haemosiderosis. In the present study we demonstrate that it is not related to the consumption of iron within the range normally found in laboratory animal diets. This suggests a genetic origin, although confirmation would require further research. If so, comparison with human idiopathic haemochromatosis is tempting. However, contrary to the human condition, organs other than the spleen are not affected, with exception of the liver. This organ contains minor deposits of pigment granules. Nor do affected animals appear to show any ill effects. Nevertheless, it seems worthwhile to investigate whether this phenomenon in C57BL mice could serve as a model for the human disease provided that a practical criterium becomes available for detection in the intact animal.
Subject(s)
Hemochromatosis/pathology , Hemosiderosis/veterinary , Mice, Inbred C57BL/metabolism , Pigmentation , Spleen/pathology , Animals , Female , Hemosiderosis/genetics , Macrophages/pathology , Male , Mice , Spleen/ultrastructureSubject(s)
Erythema/urine , Hydroxyindoleacetic Acid/urine , Serotonin/urine , Skin/radiation effects , Ultraviolet Rays , Adult , Animals , Anura , Female , Humans , Male , Skin Manifestations , Sunburn/urineSubject(s)
Body Temperature/radiation effects , Catecholamines/physiology , Hypothalamus/radiation effects , Radiation Effects , Serotonin/metabolism , Adrenergic alpha-Antagonists/pharmacology , Adrenergic beta-Antagonists/pharmacology , Amphetamine/pharmacology , Animals , Body Temperature Regulation , Cats , Electronics , Ergotamine/pharmacology , Hydrocarbons, Halogenated/pharmacology , Hypothalamus/physiology , Phentolamine/pharmacology , Propranolol/pharmacology , Rabbits , Rectum , Reserpine/pharmacology , Serotonin Antagonists , Thermometers , Tranylcypromine/pharmacologySubject(s)
Body Temperature/radiation effects , Leukocytes/radiation effects , Radiation Effects , Adrenal Glands/physiology , Adrenalectomy , Animals , Body Temperature/drug effects , Body Temperature Regulation/drug effects , Body Temperature Regulation/radiation effects , Dose-Response Relationship, Radiation , Ergotamine/pharmacology , Hypothalamus/radiation effects , Phentolamine/pharmacology , Propranolol/pharmacology , Rabbits , Sotalol/pharmacology , Theophylline/pharmacology , Time FactorsABSTRACT
The radiation-induced release of serotonin (5-HT) in rabbits and mice has a linear dose-response relationship over a short range of approximately 0.75 Gy. In both animal species a threshold value is present, which is 1 Gy for rabbits and 5 Gy for mice. Doses higher than those falling in the linear range give rise to lower plasma 5-HT values. These lower values occur concurrent with increased splenic 5-HT levels. Stimulated 5-HT uptake of the spleen may be responsible for the diminished increase in plasma 5-HT.
Subject(s)
Radiation Dosage , Serotonin/metabolism , Animals , Dose-Response Relationship, Radiation , Female , Mice , Mice, Inbred Strains , Rabbits , Serotonin/blood , Serotonin/radiation effects , Spleen/metabolism , Spleen/radiation effectsABSTRACT
Rats exposed to three different low concentrations of ozone for 2 hr show alterations in blood plasma activity comparable to those previously observed in mice. The reactions are explained as compensatory, possibly being involved in the initial phase of adaptation development.
Subject(s)
Creatine Kinase/blood , Ozone/toxicity , Adaptation, Physiological , Animals , Ascorbic Acid/analysis , Dose-Response Relationship, Drug , Liver/analysis , Lung/enzymology , Male , Rats , Rats, Inbred StrainsABSTRACT
Macrophages obtained by lavage from the lungs of rats exposed to 0.1 or 0.2 mg/m3 (0.05 or 0.10 ppm) ozone (O3) for 16 h show increased activity as measured in vitro by cell adherence to nylon fiber. A difference in adherence is noticed between macrophages occurring in first or second lung washings. The latter are less sensitive to ozone stimulation. At ozone doses higher than 0.2 mg/m3, the effect disappears and is even negative for second-washing macrophages after exposure of rats to 0.8 mg/m3 (0.4 ppm). The increased activity observed after exposure to the lower levels of O3 is explained as a defensive reaction of the organism. Failure to stimulate activity or a decrease of activity, observed at the higher O3 concentrations, may point to adverse events.
Subject(s)
Lung/drug effects , Animals , Cell Adhesion/drug effects , Lung/cytology , Macrophages/drug effects , Male , Ozone , Rats , Rats, Inbred StrainsABSTRACT
Hairless albino mice have been used to test the hypothesis of circulating mediators originating from extensive dermatitis, which might be responsible for 'false'-positive patch tests and non specific hypersensitivity. Two open patch tests with 2 or 3% phenol solution were placed on one flank at an interval of 10 days. 48 h before the second application, part of the mice received an intermediate 10% phenol solution on the opposite flank. The remaining animals served as controls. In general, intermediately treated animals showed a more pronounced reaction to the second patch test as compared to the first test, i.e., a larger granulocytic infiltrate, more extensive epithelial lesions and a elevated erythematous wall. In 6 of the 22 animals, the difference was very striking. In controls, only modest differences were observed. These findings favor the hypothesis that mediators of inflammation present in the circulation strengthen the effect of weak skin irritants.